IONS: Strategic approvals and strong launches drive growth, with pipeline poised for further milestones
Multiple FDA approvals and strong product launches mark a year of strategic success, with TRYNGALZA and DAWNZERA gaining rapid traction and robust sales outlooks. Pipeline advances include siRNA programs and anticipated regulatory milestones for HBV and IgA nephropathy.Based on Ionis Pharmaceutical…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.